Co-Diagnostics, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Co-Diagnostics, Inc. (market cap ~$10M) entered into a placement agency agreement with Maxim Group LLC on July 30, 2026 to induce exercise of existing May 2026 warrants. In exchange, the company issued new unregistered common stock purchase warrants (exercise price $1.56, 5-year term) equal to 200% of warrant shares exercised. Maxim receives 7.0% cash fee on gross proceeds plus $50,000 expense reimbursement. Company locked into 32-day equity issuance blackout (through August 31, 2026) except for exempt issuances. Specific warrant or share counts not disclosed in filing; dollar amount of inducement/exercise price not quantified.
Why this rating
Significant dilutive financing/capital raise mechanism for micro-cap company; blackout period and warrant issuance create material equity overhang. Without disclosed share/dollar amounts, cannot fully assess relative size.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.